fluciclovine f18 pet/ct imaging in assessing hormone-naive men with prostate cancer that has spread to the bone

Conditions: Metastatic Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; Stage IV Prostate Cancer

Summary: this trial studies how well fluciclovine 18f pet/ct imaging works in assessing hormone-naive men with prostate cancer that has spread to the bone. fluciclovine 18f is a radioactive drug used to measure tumor growth. pet/ct uses x-rays to take pictures inside the body. comparing results of fluciclovine 18f pet/ct imaging may help doctors predict a patient's response to treatment and help plan the best treatment.

primary objectives: i. abnormal fluciclovine f18 (\[18f\] fluciclovine) uptake on visual assessment will differ by the type of metastatic lesion present (blastic, lytic, marrow, mixed). ii. maximum standardized uptake value (suvmax) and mean standardized uptake value (suvmean) on (18f) fluciclovine-positron emission tomography (pet)/computed tomography (ct) imaging will differ by the type of metastatic lesion present (blastic, lytic, marrow, mixed). secondary objectives: i. determine if a 25% or greater reduction in average (ave) suvmax or ave suvmean on (18f) fluciclovine-pet/ct imaging after completion of all radiation therapy will be predictive of increased time to biochemical failure. ii. determine the correlation between the number of lesions, their visual uptake, and semi-quantitative uptake on technetium tc-99m medronate (99mtc-mdp) bone scintigraphy and (18f) fluciclovine- pet/ct at baseline. iii. determine the correlation between the number of lesions, their visual uptake, and semi-quantitative uptake on 99mtc-mdp bone scintigraphy and (18f) fluciclovine- pet/ct after 3 and 6 cycles of treatment. outline: this is a companion imaging study to institutional review board (irb) #102312 (a phase 2 study of radium-223 and radiotherapy in hormone-naive men with oligometastatic prostate cancer to bone). patients receive fluciclovine f18 intravenously (iv) over 30 seconds and undergo pet/ct scan over 60 minutes at baseline, 3 months and at approximately 6 months of radium-223 therapy. after completion of diagnostic testing, patients are followed for 2 years.

Eligibility criteria:
inclusion criteria: * enrollment on irb #102312 (a phase 2 study of radium-223 and radiotherapy in hormone-naive men with oligometastatic prostate cancer to bone). * patients must document their willingness to be followed for up to 24 months after recruitment by signing informed consent documenting their agreement to allow access to the data obtained on irb #102312 and information and data entered into a research database. * all patients, or their legal guardians, must sign a written informed consent and health insurance portability and accountability act (hipaa) authorization in accordance with institutional guidelines. exclusion criteria: * patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator?s discretion. * patients who require monitored anesthesia for pet scanning. * patients who are too claustrophobic to undergo pet scanning.